Antibody engineering consists of modifying monoclonal antibody (mAb) sequences and/or structures to either enhance or dampen their functions. Monoclonal Abs have revolutionized the fields of diagnosis and immunotherapy for the treatment of a variety of diseases, particularly in cancer therapy. A challenging issue remains: the production of therapeutic mAbs and Ab-derived drugs with the highest objective response rate in patients and the lowest toxicity [1-3]. Therefore, Ab engineering is a major translational research topic which aims at producing highly specific and effective mAbs, with optimal processing, stability, and tolerance .
Monoclonal Abs display a dual activity inherent to their structure:
- the variable region specifically binds one antigen
- the “fragment crystallizable” Fc in the constant region mediates effector functions, such as antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), or complement-dependent cytotoxicity (CDC) .
InvivoGen offers a broad range of reagents to:
- design, generate and purify your mAbs
- assess and compare the functions of your mAbs using our cellular assays and our extensive clinically-relevant mAb collection.